EURIPIDES
EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances
| Coordinatore | UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Sito del progetto | http://www.euripides-europe.com/ |
| Totale costo | 9˙086˙523 € |
| EC contributo | 6˙994˙850 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-A |
| Funding Scheme | CP-IP |
| Anno di inizio | 2008 |
| Periodo (anno-mese-giorno) | 2008-02-01 - 2012-07-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | coordinator | 0.00 |
| 2 |
"NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""
Organization address
address: Patriarchou Gregoriou Str. contact info |
EL (AGHIA PARASKEVI) | participant | 0.00 |
| 3 |
AIT Austrian Institute of Technology GmbH
Organization address
address: Donau-City-Strasse 1 contact info |
AT (WIEN) | participant | 0.00 |
| 4 |
GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG GAB O
Organization address
address: Oskar-von-Miller-Ring 29 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 5 |
HOSPICES CIVILS DE LYON
Organization address
address: 3 Quai des Celestins contact info |
FR (LYON) | participant | 0.00 |
| 6 |
LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN
Organization address
address: GESCHWISTER SCHOLL PLATZ 1 contact info |
DE (MUENCHEN) | participant | 0.00 |
| 7 |
MEDIZINISCHE UNIVERSITAET WIEN
Organization address
address: SPITALGASSE 23 contact info |
AT (WIEN) | participant | 0.00 |
| 8 |
REGION HOVEDSTADEN
Organization address
address: KONGENS VAENGE 2 contact info |
DK (HILLEROD) | participant | 0.00 |
| 9 |
Stichting Epilepsie Instellingen Nederland
Organization address
address: Achterweg 5 contact info |
NL (Heemstede) | participant | 0.00 |
| 10 |
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER
Organization address
address: BUNTEWEG 2 contact info |
DE (HANNOVER) | participant | 0.00 |
| 11 |
THE UNIVERSITY OF LIVERPOOL
Organization address
address: Brownlow Hill, Foundation Building 765 contact info |
UK (LIVERPOOL) | participant | 0.00 |
| 12 |
THE UNIVERSITY OF MANCHESTER
Organization address
address: OXFORD ROAD contact info |
UK (MANCHESTER) | participant | 0.00 |
| 13 |
UNIVERSITEIT LEIDEN
Organization address
address: RAPENBURG 70 contact info |
NL (LEIDEN) | participant | 0.00 |
| 14 |
VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG
Organization address
address: De Boelelaan 1105 contact info |
NL (AMSTERDAM) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). Overactivity of these efflux transporters results in inadequate access of CNS drugs to their targets and hampers the build up of adequate tissue levels of these drugs in the brain, greatly limiting their therapeutic efficacy. As such, this 'transporter hypothesis' of drug resistance is applicable to a broad range of CNS drugs and patients with a variety of CNS diseases who critically depend on these drugs. Efflux transporters may also influence brain elimination of Aβ, the hallmark of Alzheimer’s disease (AD). Impaired multidrug transporter function with reduced clearance of Aβ could lead to accumulation within the extracellular space, contributing to the pathogenesis of AD. We will determine the contribution of multidrug transporters to impaired brain uptake of drugs for the prediction of therapeutic responses, or the contribution of impaired transporter function to reduced clearance of toxic substances for the early in-vivo diagnosis of AD. Circumvention of pharmacoresistance, or increasing clearance, may involve inhibitors of multidrug transporters or sophisticated alternative therapies, but demonstration of overexpression or underactivity of transporter function is an essential and necessary first step. An in-vivo imaging biomarker of multidrug transporter function is essential for identifying altered transporter activity in individual patients. If a relation between overexpression and therapy resistance, or underactivity and AD, can be demonstrated, such a biomarker will provide the means for predicting treatment response, or early diagnosis, in individual patients.'
Altri progetti dello stesso programma (FP7-HEALTH)
PROFNAIT (2012)
Development of a prophylactic treatment for the prevention of fetal/neonatal alloimmune thrombocytopenia (FNAIT)
Read MoreEMPERIE (2009)
European Management Platform for Emerging and Re-emerging Infectious disease Entities
Read MoreEUROHYP-1 (2012)
"European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke"
Read More